DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension
Completed
Gilead Sciences
Phase 3
This is a research study of a new experimental drug called darusentan. Darusentan is not
currently approved by the U.S. Food and Drug Administration (FDA) for use in the United
States, which means that a doctor cannot prescribe this drug. The purpose of this study is to
determine if darusentan is effective in reducing systolic blood pressure in subjects with
resistant systolic hypertension, despite treatment with full doses of three or more
antihypertensive drugs, including a diuretic.
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
Terminated
Gilead Sciences
Phase 3
This is a research study of a new experimental drug called darusentan. Darusentan is not
currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in
the U.S., which means that a doctor cannot prescribe this drug. The purpose of this study is
to evaluate the long-term safety of darusentan in subjects with resistant systolic
hypertension despite treatment with full doses of three or more antihypertensive medications,
including a diuretic.
A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
Completed
Gilead Sciences
Phase 2
This is a research study of a new experimental drug called darusentan. Darusentan is not
currently approved by the U.S. Food and Drug Administration (FDA) for use in the United
States, which means that a doctor cannot prescribe this drug. The purpose of this study is to
determine if darusentan is effective in reducing systolic blood pressure in subjects with
resistant systolic hypertension, despite treatment with full doses of three or more blood
pressure lowering drugs, including a diuretic.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
